Thomasville National Bank Raises Stake in Becton, Dickinson and Company (NYSE:BDX)

Thomasville National Bank lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,627 shares of the medical instruments supplier’s stock after buying an additional 238 shares during the quarter. Thomasville National Bank’s holdings in Becton, Dickinson and were worth $374,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Alpha Omega Wealth Management LLC lifted its position in shares of Becton, Dickinson and by 0.6% during the 4th quarter. Alpha Omega Wealth Management LLC now owns 8,004 shares of the medical instruments supplier’s stock worth $2,003,000 after buying an additional 44 shares during the last quarter. Verdence Capital Advisors LLC increased its holdings in shares of Becton, Dickinson and by 1.8% in the 4th quarter. Verdence Capital Advisors LLC now owns 2,572 shares of the medical instruments supplier’s stock valued at $644,000 after acquiring an additional 45 shares during the period. Valeo Financial Advisors LLC increased its holdings in shares of Becton, Dickinson and by 3.6% in the 4th quarter. Valeo Financial Advisors LLC now owns 1,350 shares of the medical instruments supplier’s stock valued at $338,000 after acquiring an additional 47 shares during the period. Central Bank & Trust Co. increased its holdings in shares of Becton, Dickinson and by 2.4% in the 4th quarter. Central Bank & Trust Co. now owns 2,048 shares of the medical instruments supplier’s stock valued at $512,000 after acquiring an additional 48 shares during the period. Finally, IFP Advisors Inc increased its holdings in shares of Becton, Dickinson and by 1.3% in the 4th quarter. IFP Advisors Inc now owns 3,883 shares of the medical instruments supplier’s stock valued at $977,000 after acquiring an additional 48 shares during the period. Institutional investors and hedge funds own 83.22% of the company’s stock.

A number of equities analysts have recently commented on the stock. Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 target price on the stock. in a report on Wednesday, January 13th. Wells Fargo & Company cut shares of Becton, Dickinson and from an “overweight” rating to an “equal weight” rating and set a $265.00 price objective on the stock. in a research note on Tuesday, December 15th. Morgan Stanley raised shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $262.00 to $297.00 in a research note on Tuesday, December 15th. The Goldman Sachs Group cut shares of Becton, Dickinson and from a “conviction-buy” rating to a “buy” rating in a research note on Tuesday, December 15th. Finally, TheStreet raised shares of Becton, Dickinson and from a “c+” rating to an “a-” rating in a research note on Thursday, February 4th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $281.08.

NYSE:BDX opened at $244.02 on Thursday. The firm has a market cap of $70.90 billion, a price-to-earnings ratio of 89.38, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. The company has a current ratio of 1.54, a quick ratio of 1.07 and a debt-to-equity ratio of 0.72. The company’s 50-day moving average is $243.71 and its two-hundred day moving average is $243.60. Becton, Dickinson and Company has a 12-month low of $219.50 and a 12-month high of $284.97.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.14 by $1.41. The company had revenue of $5.32 billion for the quarter, compared to analyst estimates of $4.87 billion. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The firm’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.65 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 12.5 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 31st. Stockholders of record on Wednesday, March 10th were issued a dividend of $0.83 per share. The ex-dividend date was Tuesday, March 9th. This represents a $3.32 annualized dividend and a dividend yield of 1.36%. Becton, Dickinson and’s payout ratio is currently 32.55%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.